Jeil Pharmaceutical제일약품
271980 · KOSPI · ₩271980 · 제일약품
- Market cap
- ₩130B
- Enterprise value
- ₩177B
- P/E
- 13.9×
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- 4.5%
- Net margin
- 1.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−54.2% from the high
₩8,670Today: ₩8,670 – ₩8,900₩19,290
Returns
- 1W−2.4%
- 1M−11.2%
- 3M−4.3%
- 6M−36.9%
- YTD−41.7%
- 1Y−39.5%
- Volume today
- 5,180
- 0.3× the 20-day average
- Traded today
- ₩45M
- Listed shares
- 14,704,872
- EPS (12 months)
- ₩634
- Earnings yield 7.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.3% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Jeil Pharmaceutical stock overview
Jeil Pharmaceutical (제일약품, KRX: 271980) is listed on KOSPI, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩8,830 on Oct 29, 2026, unchanged on the day, giving it a market value of ₩130B.
Key facts
- Market cap
- ₩130B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 29, 2026
- Main business
- , Ltd.
Quick answers about Jeil Pharmaceutical
- What does Jeil Pharmaceutical do?
- , Ltd. is a South Korean company, spun off from Je-il Pharmaceutical's prescription drug business in 2017, that manufactures and sells finished pharmaceutical products. Its main products include the new drug Jaqubo (Jacubo) for erosive reflux esophagitis, alongside products such as Lipitor, Rosedu and Lonsurf, many of which are marketed under licensed brands.
- What is the market cap of Jeil Pharmaceutical?
- The market capitalisation of Jeil Pharmaceutical was ₩130B at the close on Oct 29, 2026.
- Who are the largest shareholders of Jeil Pharmaceutical?
- According to the latest official filings, the largest reported holders are Han Seung-su (62.46%, as of Apr 30, 2026); National Pension Service (0.70%, as of Dec 31, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.13%, as of Jul 31, 2026).
- When is the next earnings report from Jeil Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Jeil Pharmaceutical filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Jeil Pharmaceutical?
- Yes. The National Pension Service held 0.70% of Jeil Pharmaceutical shares as of Dec 31, 2025.
Company profile
Je-il Pharm Co., Ltd. is a South Korean company, spun off from Je-il Pharmaceutical's prescription drug business in 2017, that manufactures and sells finished pharmaceutical products. Its main products include the new drug Jaqubo (Jacubo) for erosive reflux esophagitis, alongside products such as Lipitor, Rosedu and Lonsurf, many of which are marketed under licensed brands. Its subsidiary, Onconic Therapeutics, conducts new drug development research and development.
Written by AI from the company's latest annual report.
- Korean name
- 제일약품
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 성석제, 한상철 (공동대표)
- Founded
- Jun 2017
- Listed
- Jul 2017
- Listed shares
- 14,704,872
- Fiscal year ends
- Month 12
- Website
- www.jeilpharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Disclosure of Corporate Governance ReportJun 1, 2026
- Amended: Quarterly report (Mar 2026)May 18, 2026
- Quarterly report (Mar 2026)May 15, 2026
- 5%+ holding reportApr 30, 2026
Titles in Korean until English translations are added.
Also known as: Jeil Pharmaceutical / 제일약품 / 271980 / KRX:271980
Source: KRX statistical information